ORGARAN

This brand name is authorized in Austria, Canada, Finland, France, Ireland, Japan, Netherlands.

Active ingredients

The drug ORGARAN contains one active pharmaceutical ingredient (API):

1	Danaparoid UNII 5004UU3156 - DANAPAROID SODIUM
	Danaparoid has been shown both in animal models and in human studies to be an effective antithrombotic substance. At therapeutic doses danaparoid has no or only a minor effect on haemostatic plug formation, platelet function and platelet aggregability with no significant effect on bleeding time at the recommended doses.
	Read more about Danaparoid

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
Orgaran	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AB09	Danaparoid	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AB Heparin group
Discover more medicines within B01AB09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02129043
FI	Lääkealan turvallisuus- ja kehittämiskeskus	052951
FR	Base de données publique des médicaments	69449143
JP	医薬品医療機器総合機構	3339600A1030
NL	Z-Index G-Standaard	13888285
NL	Z-Index G-Standaard, PRK	34339